Table 2.

Study end points with and without DHT gel treatment (±sd)

	Placebo			DHT gel
	Day 0 Baseline	Day 28 End-of-treatment	Day 56 4-wk recovery	Day 0 baseline	Day 28 End-of-treatment	Day 56 4-wk recovery
LH, IU/liter	4.3 ± 1.5	4.1 ± 1.8	4.8 ± 2.0	6.0 ± 5.6	4.5 ± 4.1a	6.6 ± 5.0
FSH, IU/liter	5.1 ± 3.3	5.2 ± 3.0	5.2 ± 3.0	8.1 ± 12	8.2 ± 12	8.4 ± 12.1
SHBG, μg/ml	3.5 ± 1.5	3.5 ± 1.7	3.4 ± 1.2	3.0 ± 1.5	3.1 ± 1.6	2.9 ± 1.4
DHEA, ng/ml	4.7 ± 2.3	4.1 ± 2.0	4.1 ± 2.0	5.8 ± 3.8	5.5 ± 3.8	6.3 ± 5.6
Androstenedione, ng/ml	0.8 ± 0.2	0.8 ± 0.3	0.8 ± 0.2	1.0 ± 0.3	0.8 ± 0.3a	0.9 ± 0.3
PSA, ng/ml	1.1 ± 0.6	1.0 ± 0.5	1.8 ± 0.8a	0.7 ± 0.4	0.8 ± 0.5	1.6 ± 1.0a
Prostate volume, cc	21.5 ± 4.2	21.0 ± 3.5	21.2 ± 3.9	20.3 ± 4.6	21.2 ± 4.3	21.8 ± 4.8
IPSS score	2.5 ± 2.8	1.7 ± 2.0a	1.6 ± 2.0a	2.3 ± 1.7	2.8 ± 2.6	2.6 ± 2.3
Weight, kg	93.7 ± 17.6	93.2 ± 17.6	93.3 ± 18.0	93.0 ± 16.9	93.3 ± 17.1	94.9 ± 17.2

^aP < 0.05 vs. baseline.